The #ArteraAI Prostate Test can help mitigate uncertainty around treatment choices. As the first-ever predictive test for localized #prostatecancer, the ArteraAI #ProstateTest can provide personalized results for shared decision-making. 🤝 ➡️ Learn more: artera.ai

In the first known study of its kind, #ArteraAI's Paul Gerrard et al describe the analytical validation of clinical-grade #AI algorithms for the ArteraAI #ProstateTest, demonstrating the robustness of the test in a lab setting, in @AI_PrecisionOnc: bit.ly/4d5OoFs

We welcomed urologists at #AUA24 to learn more about the ArteraAI Prostate Test in an insightful discussion with Dr. Neal Shore, an early adopter, to showcase the impact that the ArteraAI #ProstateTest can have on clinical practice & patient treatment decisions. #ArteraOnTheGo

Have you heard? 📣 The ArteraAI #ProstateTest has been included in @NCCN's Clinical Practice Guidelines for Prostate Cancer, making it the first #AI-enabled tool of its kind to be recommended for localized #prostatecancer! Read more from @TargetedOnc: bit.ly/3vqHGJd

The ArteraAI #ProstateTest is the first test that can both predict therapy benefit and prognosticate long-term outcomes in localized #prostatecancer. ➡️ Explore the #ArteraAI Prostate Test report and how it can help personalize prostate cancer treatment: artera.ai/arteraai-prostate-…

ArteraAI is excited to participate in the #LUGPA2023 Annual Meeting! 🌴 Visit our team at booth #110 to learn how our multimodal AI #prostatetest provides individualized results, enabling personalized treatment decision-making between clinicians and patients. #ArteraOnTheGo

In an interview with @FoxNews, @DrSpratticus, @UHhospitals, discusses how ArteraAI’s #ProstateTest is helping him identify optimal therapies for patients. ➡️ Learn how we're using the power of AI to personalize cancer care: artera.ai #ProstateCancerAwarenessMonth

The ArteraAI #ProstateTest can predict therapy benefit & prognosticate long-term outcomes in localized #prostate cancer, with AI models developed using clinical trial data comprising approximately 20% African American men: artera.ai/ #PersonalizingProstateCancerCare

In an interview with @urotoday, Ashley Ross, MD, Ph.D., @NorthwesternU, discusses how we define risk in localized #prostatecancer, and how the #ArteraAI #ProstateTest can help clinicians better risk stratify patients and individualize their care: bit.ly/409hlZS

Artera was thrilled to announce its public launch earlier this month, with $90M in funding to help distribute the ArteraAI #ProstateTest globally. 🌎 The test is the first to predict therapy benefit in localized #prostatecancer: bit.ly/3LIHfzv

Did you catch Tim Showalter's presentation at #BiomarkersSeries23? 🇬🇧 Members of the Artera team met with attendees to discuss how the #ArteraAI #ProstateTest can help identify patients who will benefit from therapy intensification. ➡️ Learn more: artera.ai/our-test/

Standard prognostic tools for #prostatecancer can rely on non-specific and semi-quantitative tools, which may lead to over/under-treatment. ➡️ The #ArteraAI #prostatetest uses AI to estimate long-term, clinically relevant outcomes: artera.ai/our-science/

What if there was a way to identify the patients who would benefit from therapy intensification? With #ArteraAI, there is. 💙 ➡️ Learn more about The ArteraAI #ProstateTest: artera.ai/our-test

The Artera team is heading to #BiomarkersSeries23 2/27-2/28 in Manchester. 🇬🇧 Don't miss Dr. Tim Showalter's presentation "Pathology-Based Deep Learning Tools to Personalize Treatment Decisions: #ArteraAI #ProstateTest Development & Validation" on 2/27! bit.ly/3XEatCb

Genechron sabato presenterà presso il convegno di Auro.it - Associazione Urologi Italiani il nuovo test #MPT (Mitomic #ProstateTest) della società @MDNALifeSci di cui è il distributore esclusivo in Italia auro.it/wp-content/uploads/2…

SUPPORT THIS ACROSS THE WORLD. #prostatecancer #prostatetest x.com/COncometrix